NCT01617096View on ClinicalTrials.gov

Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

PHASE3CompletedINTERVENTIONAL
Enrollment

2,629

Participants

Timeline

Start Date

July 24, 2012

Primary Completion Date

July 3, 2015

Study Completion Date

December 31, 2015

Conditions
HIV Infections
Interventions
COMBINATION_PRODUCT

Dapivirine Vaginal Ring

Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months

COMBINATION_PRODUCT

Placebo Ring

Vaginal ring containing no drug substance

Trial Locations (7)

Unknown

College of Medicine - Johns Hopkins University Research Project, Blantyre

UNC Project, Lilongwe

CAPRISA, eThekwini Clinical Research Site, Durban

Desomond Tutu HIV Center, Cape Town

Wits Reproductive Health and HIV Institute, Johannesburg

MU-JHU Care LTD, MU-JHU Research Collaboration, Kampala

UZ-Obstetrics & Gynecology Research Clinic at Spillhaus, Belgravia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT01617096 - Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women | Biotech Hunter | Biotech Hunter